Treat depression. Differently.
Provide your patients with an effective1 and side-effect-free depression treatment option2.
Join more than 50 clinics and build Flow into your depression treatment pathway.
Treat depression. Differently.
Provide your patients with an effective1 and side-effect-free depression treatment option2.
Join more than 50 clinics and build Flow into your depression treatment pathway.
Address patient needs
With 75%3 of patients wanting a drug-free depression treatment, and over 1.4 million in the UK alone waiting to see a therapist4, an alternative depression treatment is needed.
Flow is the first clinically validated platform that delivers an effective1, drug-free depression treatment that directly targets the physical causes of depression from the comfort of patient homes. Combining a safe, easy-to-use brain stimulation wearable with a guided app program and overarching clinician remote monitoring portal, Flow’s engineers and clinicians have created a measurable alternative depression treatment.
No major side effects
For the majority taking antidepressants, side effects are inevitable5. Studies show that antidepressants often impact libido, appetite and energy levels6.
Depression treatment can be side effect free. tDCS longitudinal studies report no major adverse events7. Flow’s real-world data also shows less than 2% (from 7500+ patients) reporting minor side effects such as headaches and skin irritation2.
Approved for at-home use across the UK and EU
FDA breakthrough device designation for at-home depression treatment
Approved by the British Standards Institutions (BSI)
Class IIa medical device CE-marked. Approved for in the EU and UK
Tested according to IEC 60601 for electrical medical device safety
Efficacy on par with antidepressants and TMS
Clinical studies show that tDCS is as effective as antidepressants as well as TMS8-9. Specific Flow clinical trials show Flow is associated with a 60-88% remission rate10-11 while clinical trials reviewing antidepressants show a remission rate of 40%12-13.
Flow in practice
7,500+ users with a 60% adherence rate across the board2
50+ clinics in the UK and EU formally offering Flow
Multiple NHS pilots from primary care setting to TMS specialists
From mild to severe, 83% have seen improvements
In the largest tDCS study to date, 24% of patients go into remission, while 41% had a clinical response after 6 weeks of using this technique14.
Within a few weeks, the Flow treatment is associated with supporting improvements in mood, concentration, optimism and initiative, while reducing anxiety and suicidal thoughts2.
Flow in the media
References
1. Fu Cynthia H.Y., et al. J Psychiatric Research. 2022;153:197-205. 2. Data on File. 3. McHugh RK, et al. J Clin Psychiatry. 2013;74(6):595-602. 4. Outpatient Mental Health Access and Workforce Crisis Issue Brief. Association for Behavioral Healthcare. 2022. 5. Read J, Williams J. Curr Drug Saf. 2018;13(3):176-186. 6. Carvalho AF, et al. Psychother Psychosom. 2016;85(5):270-88. 7. Chhabra Harleen et al. Psychiatry Res; 284, 2020. 8. Mutz J, et al. BMJ. 2019;364:l1079. 9. Brunoni AR, et al. JAMA Psychiatry. 2013;70(4):383-91. 10. Borrione L, et al. J Affect Disord. 2021;288:189-190. 11. Fu Cynthia H.Y., et al. J Psychiatr Res. 2022;153:197-205. 12. Machado M, et al. Current medical research and opinion. 2006;22(9),1825–1837. 13. Thase ME, et al. J Clin Psychiatry. 2005;66(8), 974–981. 14. Brunoni AR, et al. N Engl J Med. 2017; 376:2523-2533.